Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
Corvus Pharmaceuticals (NASDAQ: CRVS) will present a corporate overview and hold one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference in New York and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami.
The Jefferies presentation is on June 3, 2026 at 3:45 PM ET, and the Goldman Sachs presentation is on June 8, 2026 at 11:20 AM ET. Live webcasts and 90-day replays will be available via Corvus' investor relations website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CRVS
On the day this news was published, CRVS gained 7.30%, reflecting a notable positive market reaction. Argus tracked a peak move of +25.7% during that session. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $71M to the company's valuation, bringing the market cap to $1.05B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CRVS shows a +8.09% move with mixed peer action: PRTA -0.22%, ALMS -2.5%, REPL -3.89% versus ATXS +0.8% and ITOS +0.1%, pointing to a stock-specific move rather than a broad biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 14 | Phase 1 data | Positive | -13.8% | Final Phase 1 soquelitinib atopic dermatitis data with strong efficacy and safety. |
| May 07 | Q1 2026 earnings | Positive | +6.6% | Q1 2026 results, positive clinical progress, and cash runway into Q2 2028. |
| Apr 23 | Board appointment | Positive | -10.3% | Appointment of experienced immunology leader Andrew C. Chan to Board. |
| Apr 21 | Investor meeting | Positive | +10.3% | Announcement of May 14 investor meeting on final Phase 1 soquelitinib data. |
| Mar 12 | FY 2025 results | Positive | -4.3% | Q4/FY 2025 update and public offering extending cash runway into Q2 2028. |
Recent news with generally positive tone has often seen mixed or contrary price reactions, with several divergences following seemingly favorable clinical and corporate updates.
Over the past few months, CRVS has reported multiple milestones: positive soquelitinib Phase 1 atopic dermatitis data, Q1 2026 results with cash projected into Q2 2028, and a board appointment aimed at strengthening scientific oversight. Price reactions have been inconsistent, including selloffs after favorable clinical and management news and gains around investor events and some earnings updates. Today’s conference participation announcement fits into an active period of investor outreach and clinical advancement but does not itself add new clinical or financial data.
Regulatory & Risk Context
An effective S-3ASR shelf filed on 2026-03-13 allows CRVS to offer common stock, preferred stock, debt securities, warrants, and units over time, with at least one 424B5 usage already recorded. Specific total capacity details were not provided in the summary.
Market Pulse Summary
The stock moved +7.3% in the session following this news. A strong positive reaction aligns with growing investor attention around CRVS’s clinical pipeline and recent financing strength, even though this conference notice adds no new efficacy or financial data. Prior news saw mixed follow-through, with several positive items followed by double-digit pullbacks. High volatility and existing shelf capacity could introduce dilution or trading reversals, so past patterns of divergence after good news may inform views on sustainability.
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2026 Jefferies Global Healthcare Conference, to be held in New York, NY, and the Goldman Sachs 47th Annual Global Healthcare Conference, to be held in Miami, FL. The Jefferies presentation is scheduled for Wednesday, June 3, 2026 at 3:45 PM ET, and the Goldman Sachs presentation is scheduled for Monday, June 8, 2026 at 11:20 AM ET.
A webcast of the presentations will be available live and for 90 days following the events. The webcasts may be accessed via the investor relations section of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 2 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Julia Stern
Real Chemistry
+1-763-350-5223
jstern@realchemistry.com
